Back to News
Market Impact: 0.35
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Source: businesswire.com
Healthcare & BiotechCompany Fundamentals
Divarasib demonstrated what the company described as best-in-class efficacy in a Phase III trial for previously treated KRAS G12C-mutated lung cancer. The result was presented as advancing the standard of care; the article provides no efficacy figures or further trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- SpaceX closes $40 billion debt deal for AI chips, Elon Musk says
- Earnings playbook: Alphabet, Microsoft, Amazon and more report this week. Here's what to expect
- More pain may be coming for the AI trade. Why I’m not giving up on it
- AI Spending Fears Threaten to Swamp Big Tech’s Strong Earnings
- Apple to Unveil Touch-Screen MacBook Pro; Executive Promotions; In-Box Checker
- Musk Says SpaceX Closed $40 Billion Debt Deal, Blasts Neoclouds